Close Menu

financial guidance

The company's revenues were in line with analyst expectations, while its adjusted earnings per share of $.87 beat expectations.

The company missed its expectations due to declining orders for its HiSeq 2500 and HiSeq 4000 instruments and one fewer order for its HiSeq X Ten system.

Coming off a nearly 9 percent rise in July, the GenomeWeb Index fell more than 2 percent in August, mimicking the Nasdaq Biotechnology Index, which fell 3 percent.

The company said it achieved record volumes for its AlloMap non-invasive blood test for heart transplant patients.

After reporting FY2016 revenues below market expectations, Myriad discussed plans to increase sales of Prolaris, Vectra DA, EndoPredict, GeneSight, and myChoice HRD.

The company credited the increased revenues to a 12 percent rise in the number of Oncotype Dx tests delivered.

The firm completed its acquisition of Nanosphere on June 30, and received FDA clearance and CE-IVD marking for the Aries M1 system on July 6.

The company said its organic revenue growth during the quarter was 4 percent, and that acquisitions increased revenue by 3 percent.

Revenues from the company’s molecular diagnostics business grew 6 percent, driven by continued strength in sales of women's health products.

The company said it completed about 54,000 Cologuard tests in Q2, and that the cumulative number of physicians ordering the test since its launch has risen to 41,000.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.